阿拉坦五味丸联合莫沙必利治疗功能性消化不良的疗效观察

目的观察阿拉坦五味丸联合莫沙必利治疗功能性消化不良的临床疗效。方法选取2014年1月—2015年1月海口市龙华区遵谭镇卫生院收治的功能性消化不良患者140例,以就诊单双号为标准进行分组,每组各70例。对照组口服枸橼酸莫沙必利分散片,1片/次,3次/d。治疗组在对照组基础上给予阿拉坦五味丸,温水口服,11~15粒/次,1~2次/d。两组均持续治疗4周。观察两组的临床疗效,同时比较两组治疗前后临床症状评分、幽门螺杆菌阳性率、不良反应和复发情况。结果治疗后,治疗组的总有效率(95.71%)明显高于对照组(85.71%),两组比较差异有统计学意义(P0.05)。治疗后,两组患者嗳气、反酸、烧心、食欲不振、恶心呕吐和上腹不适的症状评分均较治疗前显著下降,同组治疗前后差异具有统计学意义(P0.05);且治疗组这些观察指标的改善程度优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组幽门螺杆菌阳性率均较治疗前显著降低下降,同组治疗前后差异具有统计学意义(P0.05);且治疗组这些观察指标的改善程度优于对照组,两组比较差异具有统计学意义(P0.05)。结论阿拉坦五味丸联合莫沙必利治疗功能性消化不良具有较好的临床疗效,能显著改善临床症状,降低幽门螺杆菌阳性率,不良反应较少,复发率低,具有一定的临床推广应用价值。

Clinical observation of Alatan Wuwei Pills combined with mosapride in treatment of functional dyspepsia

Objective To observe the clinical effect of Alatan Wuwei Pills combined with mosapride in treatment of functional dyspepsia. Methods Patients (140 cases) with functional dyspepsia from January 2014 to January 2015 were divided into control and treatment groups according to the visiting single or even numbers, and each group had 70 cases. The patients in the control group were po administered with Mosapride Citrate Dispersible Tablets, 1 tablet/time, three times daily. The patients in the treatment group were po administered with Alatan Wuwei Pills on the basis of the control group, 11—15 pills/time, once or twice daily. The patients in two groups were treated for four weeks. The clinical efficacies of the two groups were observed; And clinical symptoms scores, helicobacter pylori positive rate, adverse reactions and recurrence before and after treatment were compared between two groups. Results After treatment, the clinical efficacy of patients in treatment group (95.71%) were higher than those in control group (85.71%) with significant difference (P < 0.05). After treatment, the scores of eructation, acid regurgitation, heartburn, loss of appetite, nausea and vomiting, and epigastric discomfort in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the helicobacter pylori positive rates in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational index in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Alatan Wuwei Pills combined with mosapride has clinical curative effect in treatment of functional dyspepsia, and can significantly improve clinical symptoms, reduce helicobacter pylori positive rate, less adverse reactions and lower recurrence rate, which has a certain clinical application value.